Navigation Links
Modell Chair in Pediatric Immunology established
Date:2/16/2011

The Children's Hospital of Philadelphia has announced the establishment of the Jeffrey Modell Endowed Chair in Pediatric Immunology Research.

A ceremony on Feb. 15 at the Hospital's Ruth and Tristram Colket, Jr. Translational Research Building recognized the first holder of the chair, pediatric immunologist Jordan S. Orange, M.D., Ph.D. The chair's $2 million endowment will allow Dr. Orange to break new ground in his ongoing research. Dr. Orange is internationally prominent for studying and treating primary immunodeficiency disorders in children.

"We appreciate the generosity of Fred and Vicki Modell for their continuing support of Dr. Orange's important work," said Steven M. Altschuler, M.D., chief executive officer of The Children's Hospital of Philadelphia. "This gift will advance the efforts by Dr. Orange and the Jeffrey Modell Foundation to translate scientific knowledge into real improvements in children's lives."

Dr. Altschuler presented the endowed chair to Dr. Orange. Fred and Vicki Modell spoke at the ceremony, as did Alan R. Cohen, M.D., physician-in-chief of Children's Hospital.

Dr. Orange is already the director of the Jeffrey Modell Diagnostic Center at Children's Hospital, a premier program among dozens of centers worldwide that have been established by the Jeffrey Modell Foundation to provide expert diagnosis and treatment to patients with primary immunodeficiency diseases. Co-founded by Fred and Vicki Modell in 1986, the Foundation honors the memory of their son Jeffrey, who died at age 15 from complications of primary immunodeficiency.

Primary immunodeficiencies include over 150 genetic disorders in which the immune system's ability to produce specific antibodies to fight off infection is greatly impaired or absent. Early diagnosis and treatment are essential to preventing recurrent infections from doing permanent damage.

Dr. Orange's research focuses on the biology of natural killer cells and the innate immune system, with a clinical focus on primary immunodeficiency disease. He has received funding from the National Institute of Allergy and Infectious Diseases and the United States Immunodeficiency Network to support his laboratory work, and has authored over 100 scientific publications. In 2009 the American Philosophical Society awarded him the Judson Daland Prize for Clinical Investigation, which honors outstanding achievements in patient-oriented research.

Over the past decade, Dr. Orange has redefined the field of human natural killer cell deficiencies in various genetic disorders. He recently collaborated with European researchers who achieved marked clinical improvements in using gene therapy to treat young children with Wiskott-Aldrich syndrome, a rare but often severe immunodeficiency disorder. At Children's Hospital, he is currently conducting clinical trials testing the use of immunotherapy to boost immune function in children with Wiskott-Aldrich syndrome.

In addition to his duties at The Children's Hospital of Philadelphia, Dr. Orange is on the Pediatrics faculty of the University of Pennsylvania School of Medicine and is an elected member of the American Society for Clinical Investigation.


'/>"/>

Contact: Rachel Salis-Silverman
Salis@email.chop.edu
267-426-6063
Children's Hospital of Philadelphia
Source:Eurekalert

Related biology news :

1. Clinical trial shows quadriplegics can operate powered wheelchair with tongue drive system
2. McGill garners 19 Canada Research Chairs and more than $17 million in funding
3. Study shows that color plays musical chairs in the brain
4. New biomedical engineering chair earns high honors
5. Salk Institute creates Renato Dulbecco Chair in Genomics and Roger Guillemin Chair in Neuroscience
6. Armchair nanoribbons made into spintronic device
7. Innovations in Pediatric Medicine CME conference brings together national pediatrics experts
8. Innovations in Pediatric Medicine International Conference brings together pediatrics experts
9. Gene mutation increases drug toxicity, rejection risk in pediatric kidney transplants
10. Childrens Hospital Oakland is first pediatric hospital to use laboratory-on-a-card technology
11. Childrens National experts present at Pediatric Academic Societies Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2017)... --  Strategic Cyber Ventures , the industry,s first cybersecurity ... million investment in  Polarity , the first commercial human ... based and is led by cybersecurity veterans Tom ... Gula , also a longtime cybersecurity veteran and founder ... A round of funding. This new funding will be ...
(Date:2/21/2017)... Der weltweite Biobanking-Sektor wird bis ... Gespräch mit mehr als 50 Vertretern aus verschiedenen Branchen wurde ... um diese Prognose zu realisieren. ... Zu den Schwierigkeiten ... Mittel für die Biobank, die Implementierung Zeit sparender Technologien, ...
(Date:2/10/2017)... Research and Markets has announced the addition of ... Commercial Aspects" to their offering. ... Biomarkers play an important ... selection of treatment as well for monitoring the results. There ... modern medicine. Biochip/microarray technologies and next generation sequencing are also ...
Breaking Biology News(10 mins):
(Date:3/23/2017)... 23, 2017  GlobeImmune, Inc. today announced it has ... of 12,835,490 shares of its common stock to NantCell, ... connection with the sale of its common stock, NantCell ... issue to GlobeImmune 200,000 shares, an estimated $2.0 million ... "We are pleased to enter into this strategic agreement ...
(Date:3/23/2017)... March 23, 2017 NetworkNewsWire Editorial Coverage  ... Cancer ... significant strain on health care systems, in terms of costs ... so too does the development of innovative and efficient therapies ... Among the many types of cancer treatments, a growing number ...
(Date:3/23/2017)... ... March 23, 2017 , ... Advanced Polymer Monitoring Technologies ... Dr. Sigmund “Sig” Floyd as Vice President ? Global Business Development. Dr. Floyd ... , “Dr. Floyd’s career has spanned 30 years in the chemicals and equipment ...
(Date:3/22/2017)... 2017  UBM and the Massachusetts Medical Device ... partnership and the third annual Massachusetts Medtech Week. Massachusetts ... st Annual MassMEDIC Conference held in conjunction ... 2017. MassMEDIC will feature a ... and CEO, Scott Whitaker , at its ...
Breaking Biology Technology: